Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Immunoglobulin for Subcutaneous Injection in Primary Immunodeficiency
CTR20213011Phase 3Completed
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Gamimune-N in Immunogenetic disorder, sponsored by Chengdu Rongsheng Pharmaceutical. Started Nov 2021; status: completed.
02
Drugs
Gamimune-N
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on CTR20213011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213011.